DNA Replication Failure Linked to Cancer Therapy: CDK4/6 and RB Tumor Suppressor Proteins Investigated

Strategic Insights -

A recent study published in Nature Communications reveals the critical role of CDK4/6 in enabling DNA replication licensing, a process crucial for cell division, and how cancer therapy works. The research team, led by Dr. Bennie Lemmens and Dr. Jiri Bartek, found that the phosphorylation of RB tumor suppressor proteins by CDK4/6 has two functions: it commits cells to divide and prepares the genome to be copied correctly. This dual role may explain why CDK4/6 inhibitors are powerful in the clinic and points the way to more effective cancer treatments.

Key Takeaways:

  • The study highlights the importance of CDK4/6 in promoting DNA replication licensing in human cells, a process crucial for cell division.
  • The phosphorylation of RB tumor suppressor proteins by CDK4/6 has a dual function: it commits cells to divide and prepares the genome to be copied correctly.
  • The researchers found that combining CDK4/6 inhibitors with other treatments that block DNA licensing causes cancer cells to divide without copying their DNA properly, leading to increased cell death in cancer cells lacking the p53 gene.
  • This study was made possible through the support of The Mark Foundation for Cancer Research, Cancerfonden, the Swedish Research Council, Karolinska Institutet, and SciLifeLab.
  • The results of the study add a new layer to our understanding of how cancer drugs work and may lead to better targeted cancer therapies in the future.

Statistics:

  • The study was published in Nature Communications.
  • The research team analyzed DNA sequencing data from thousands of sites across the human genome.
  • The phosphorylation of RB by CDK4/6 has a dual function, committing cells to divide and preparing the genome to be copied correctly.

Sources:

  • Lehrstuhl für Molekulare Biologie (Switzerland - Karolinska Institutet)
  • Nature Communications, September 16